SCHEMBL16570376

SCHEMBL16570376

CS(=O)(=O)Nc1ccccc1Cn1ccc2cnc(Nc3ccc4c(c3)OCC(=O)N4)nc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT6 P42226 4/20 0.43
▸ SYK P43405 6/20 0.42
▸ ALK Q9UM73 3/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ DCLK1 O15075 2/20 0.42
▸ AURKA O14965 1/20 0.42
▸ PDPK1 O15530 1/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ ROCK2 O75116 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ EGFR P00533 1/20 0.42
▸ NTRK1 P04629 1/20 0.42
▸ PRKCG P05129 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ FYN P06241 1/20 0.42
▸ CDK1 P06493 1/20 0.42
▸ LYN P07948 1/20 0.42
▸ RET P07949 1/20 0.42
▸ IGF1R P08069 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16571027 0.87 PTK2 (0.50) STAT6SYKALKJAK3DCLK1
SCHEMBL16571235 0.87 PTK2 (0.51) STAT6SYKALKJAK3DCLK1
SCHEMBL16570904 0.86 ULK1 (0.46) STAT6SYKALKJAK3DCLK1
SCHEMBL16570875 0.84 PTK2 (0.52) ALKJAK3AURKAPDPK1JAK2
SCHEMBL16570172 0.79 PTK2 (0.50) SYKALKJAK3AURKAPDPK1
SCHEMBL1075107 0.78 GLO1 (0.61) SYKALKJAK3AURKAGSK3A
SCHEMBL16570363 0.78 PTK2 (0.51) ALKJAK3AURKAPDPK1JAK2
SCHEMBL16580996 0.76 STAT6 (0.61) STAT6JAK3JAK2EGFRFGFR1
SCHEMBL16571003 0.74 PTK2 (0.65) ALKJAK3AURKAPDPK1JAK2
SCHEMBL16570187 0.74 JAK2 (0.48) STAT6SYKALKJAK3DCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN STAT6 103/4885SYK 5/4885ALK 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback